The KEYNOTE-o42 trial demonstrated that taking Keytruda was more effective in treating lung cancer than chemotherapy, and further findings could mean that patients can skip chemo treatment altogether. The recent stock gain represents almost $5.75 billion in market value.
Keytruda earned Merck more than $3.8 billion in sales in 2017.
More articles on business:
Boeing swipes $12B American Airlines order from rival Airbus
Viacom asks CBS to increase merger offer by $2.8B
Facebook suspends 2 more analytics companies in wake of scandal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.